Delving into the Latest Updates on CUO246 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

Bacterial DNA gyrase x Topoisomerase IV

Mechanism

Bacterial DNA gyrase modulators, Topoisomerase IV modulators(Topoisomerase IV modulators)

Therapeutic Areas

Infectious DiseasesRespiratory DiseasesOther Diseases

Active Indication

COVID-19Diagnostic agentsSchizophrenia

Inactive Indication-

Originator Organization

Novartis AG

Active Organization

Shaanxi Panlong Pharmaceutical Group Ltd. By Share Ltd.

UCSI UniversityInflamed Pharma GmbH

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

CUO246, a novel DNA gyrase/topoisomerase IV inhibitor, is active in vitro against a broad range of Gram-positive, fastidious Gram-negative, and atypical bacterial pathogens and retains activity against quinolone-resistant strains in circulation. The frequency of selection for single step mutants of wild-type S. aureus with reduced susceptibility to CUO246 was <4.64 × 10^-9 at 4× and 8× MIC and remained low when using an isogenic QRDR mutant (<5.24 × 10^-9 at 4× and 8× MIC). Biochemical assays indicated that CUO246 had potent inhibitory activity against both DNA gyrase (GyrAB) and topoisomerase IV (ParCE). Furthermore, CUO246 showed rapid bactericidal activity in time-kill assays and potent in vivo efficacy against S. aureus in a neutropenic murine thigh infection model. These results suggest that CUO246 may be useful in treating infections by various causative agents of acute skin and skin structure infections, respiratory tract infections, and sexually transmitted infections.

100 Deals associated with CUO246

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Preclinical	-	Shaanxi Panlong Pharmaceutical Group Ltd. By Share Ltd.	21 Dec 2022
Diagnostic agents	Preclinical	-	Inflamed Pharma GmbH	01 Dec 2022
Schizophrenia	Preclinical	-	UCSI University	01 Dec 2022